SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ivermectin / Pyrantel Formulation

Manufacturer or supplier’s details
Company name of supplier: MSD
Address: 2000 Galloping Hill Road
        Kenilworth - New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>&gt;= 5 &lt;- 10</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>&gt;= 1 &lt;- 5</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>&lt; 0.1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
SAFETY DATA SHEET

Ivermectin / Pyrantel Formulation

Most important symptoms and effects, both acute and delayed:
- Contact with dust can cause mechanical irritation or drying of the skin.
- Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders:
- No special precautions are necessary for first aid responders.

Notes to physician:
- Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Sulfur oxides
- Metal oxides
- Chlorine compounds

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters:
- Wear self-contained breathing apparatus for firefighting if necessary.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are
released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labeled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Further information: Skin

| Wipe limit | 0.5 mg/100 cm² | Internal |

**Engineering measures**: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**: powder

**Color**: brown

**Odor**: No data available

**Odor Threshold**: No data available

**pH**: 4 - 6 (20 °C) (as aqueous solution)

**Melting point/freezing point**: No data available

**Initial boiling point and boiling range**: No data available

**Flash point**: Not applicable
## Evaporation rate
- Not applicable

### Flammability (solid, gas)
- May form explosive dust-air mixture during processing, handling or other means.

### Flammability (liquids)
- No data available

### Upper explosion limit / Upper flammability limit
- No data available

### Lower explosion limit / Lower flammability limit
- No data available

### Vapor pressure
- Not applicable

### Relative vapor density
- Not applicable

### Relative density
- No data available

### Density
- No data available

### Solubility(ies)
- Water solubility
  - No data available

### Partition coefficient: n-octanol/water
- Not applicable

### Autoignition temperature
- No data available

### Decomposition temperature
- No data available

### Viscosity
- Viscosity, kinematic
  - Not applicable

### Explosive properties
- Not explosive

### Oxidizing properties
- The substance or mixture is not classified as oxidizing.

### Particle size
- No data available

## SECTION 10. STABILITY AND REACTIVITY

### Reactivity
- Not classified as a reactivity hazard.

### Chemical stability
- Stable under normal conditions.

### Possibility of hazardous reactions
- May form explosive dust-air mixture during processing, handling or other means.
  - Can react with strong oxidizing agents.

### Conditions to avoid
- Heat, flames and sparks.
  - Avoid dust formation.

### Incompatible materials
- Oxidizing agents

### Hazardous decomposition products
- No hazardous decomposition products are known.
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienylvinyl)]pyrimidine (1:1):
Acute oral toxicity: LD50 (Rat): > 24,000 mg/kg
LD50 (Mouse): > 24,000 mg/kg
LD50 (Dog): 2,000 mg/kg

Sodium chloride:
Acute oral toxicity: LD50 (Rat): 3,550 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 42 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 5,000 mg/kg

Ivermectin:
Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.
Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg
Skin corrosion/irritation
Not classified based on available information.

Components:

Sodium chloride:
Species: Rabbit
Result: No skin irritation

Ivermectin:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Sodium chloride:
Species: Rabbit
Result: No eye irritation

Ivermectin:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Sodium chloride:
Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Result: negative

Ivermectin:
Routes of exposure: Dermal
Species: Humans
Result: Does not cause skin sensitization.

Germ cell mutagenicity
Not classified based on available information.
Components:

4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

Sodium chloride:
Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Result: positive
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Saccharomyces cerevisiae, gene mutation assay (in vitro)
  - Result: positive
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Result: positive
- Test Type: Chromosome aberration test in vitro
  - Result: positive
- Test Type: Chromosome aberration test in vitro
  - Result: negative

Genotoxicity in vivo:
- Test Type: In vivo micronucleus test
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Result: negative
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - Species: Rat
  - Application Route: Intraperitoneal injection
  - Result: positive

Germ cell mutagenicity - Assessment:
- Weight of evidence does not support classification as a germ cell mutagen.

Ivermectin:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Test system: human diploid fibroblasts
  - Result: negative
- Test Type: Mouse Lymphoma
  - Result: negative
Carcinogenicity
Not classified based on available information.

**Components:**

**Sodium chloride:**
- Species: Rat
- Application Route: Ingestion
- Exposure time: 2 Years
- Result: negative

**Ivermectin:**
- Species: Rat
- Application Route: Oral
- NOAEL: 1.5 mg/kg body weight
- Result: negative
- Remarks: Based on data from similar materials

- Species: Mouse
- Application Route: Oral
- NOAEL: 2.0 mg/kg body weight
- Result: negative
- Remarks: Based on data from similar materials

Reproductive toxicity
Not classified based on available information.

**Components:**

4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
- Effects on fetal development: Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
  - Result: No effects on fertility and early embryonic development were detected.

  Test Type: Embryo-fetal development
  - Species: Rabbit
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
  - Result: No effects on fertility and early embryonic development were detected.

**Ivermectin:**
- Effects on fertility: Test Type: Fertility
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 0.6 mg/kg body weight
  - Result: Animal testing did not show any effects on fertility.

  Effects on fetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

STOT-single exposure
Not classified based on available information.

Components:
Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT-repeated exposure
Not classified based on available information.

Components:
Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Species: Dog
NOAEL: 10 mg/kg
LOAEL: 30 mg/kg
Application Route: Ingestion
Exposure time: 3 d
Remarks: No significant adverse effects were reported
Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 19 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

**Sodium chloride:**
Species : Rat  
LOAEL : 2,533 mg/kg  
Application Route : Ingestion  
Exposure time : 2 y

**Ivermectin:**
Species : Dog  
NOAEL : 0.5 mg/kg  
LOAEL : 1 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Central nervous system  
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey  
NOAEL : 1.2 mg/kg  
Application Route : Oral  
Exposure time : 2 Weeks  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 0.4 mg/kg  
LOAEL : 0.8 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : spleen, Bone marrow, Kidney

Aspiration toxicity  
Not classified based on available information.
Experience with human exposure

Components:

4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

**Ingestion**

- Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea, Headache, Dizziness, Fever

**Ivermectin:**

- Skin contact: Remarks: Can be absorbed through skin.
- Eye contact: Remarks: May irritate eyes.
- Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment

**Acute aquatic toxicity**

- Toxic effects cannot be excluded

**Chronic aquatic toxicity**

- Toxic effects cannot be excluded

**Sodium chloride:**

- Toxicity to fish: LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 4,136 mg/l Exposure time: 48 h
- Toxicity to algae/aquatic plants: EC50: > 2,000 mg/l Exposure time: 96 h
- Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 252 mg/l Exposure time: 33 d
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia pulex (Water flea)): 314 mg/l Exposure time: 21 d
- Toxicity to microorganisms: EC10: > 1,000 mg/l

**Ivermectin:**

- Toxicity to fish: LC50 (Onchorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h
  - LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates:

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants:

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Persistence and degradability

Components:

Ivermectin:
Biodegradability:
Result: Not readily biodegradable.
Biodegradation: 50%
Exposure time: 240 d

Bioaccumulative potential

Components:

Ivermectin:
Bioaccumulation:
Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water:
log Pow: 3.22

Mobility in soil:
No data available

Other adverse effects:
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods:
Waste from residues:
Dispose of in accordance with local regulations.
Contaminated packaging:
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number:
UN 3077
Proper shipping name:
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
SAFETY DATA SHEET

Ivermectin / Pyrantel Formulation

Class : 9
Packing group : III
Labels : 9

IATA-DGR
UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Ivermectin)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)

Class : 9
Packing group : III
Labels : 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills : Not applicable
SAFETY DATA SHEET

Ivermectin / Pyrantel Formulation

The ingredients of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

**SECTION 16. OTHER INFORMATION**

**Full text of other abbreviations**

- **AIIC**: Australian Inventory of Industrial Chemicals; **ANTT**: National Agency for Transport by Land of Brazil; **ASTM**: American Society for the Testing of Materials; **bw**: Body weight; **CMR**: Carcinogen, Mutagen or Reproductive Toxicant; **DIN**: Standard of the German Institute for Standardisation; **DSL**: Domestic Substances List (Canada); **ECx**: Concentration associated with x% response; **ELx**: Loading rate associated with x% response; **EmS**: Emergency Schedule; **ENCS**: Existing and New Chemical Substances (Japan); **ErCx**: Concentration associated with x% growth rate response; **ERG**: Emergency Response Guide; **GHS**: Globally Harmonized System; **GLP**: Good Laboratory Practice; **IARC**: International Agency for Research on Cancer; **IATA**: International Air Transport Association; **IBC**: International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; **IC50**: Half maximal inhibitory concentration; **ICAO**: International Civil Aviation Organization; **IECSC**: Inventory of Existing Chemical Substances in China; **IMDG**: International Maritime Dangerous Goods; **IMO**: International Maritime Organization; **ISHL**: Industrial Safety and Health Law (Japan); **ISO**: International Organisation for Standardization; **KECI**: Korea Existing Chemicals Inventory; **LC50**: Lethal Concentration to 50% of a test population; **LD50**: Lethal Dose to 50% of a test population (Median Lethal Dose); **MARPOL**: International Convention for the Prevention of Pollution from Ships; **n.o.s.**: Not Otherwise Specified; **Nch**: Chilean Norm; **NO(A)EC**: No Observed (Adverse) Effect Concentration; **NO(A)EL**: No Observed (Adverse) Effect Level; **NOELR**: No Observable Effect Loading Rate; **NOM**: Official Mexican Norm; **NTP**: National Toxicology Program; **NZIoC**: New Zealand Inventory of Chemicals; **OECD**: Organization for Economic Co-operation and Development; **OPPTS**: Office of Chemical Safety and Pollution Prevention; **PBT**: Persistent, Bioaccumulative and Toxic substance; **PICCS**: Philippines Inventory of Chemicals and Chemical Substances; **(Q)SAR**: (Quantitative) Structure Activity Relationship; **REACH**: Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; **SDT**: Self-Accelerating Decomposition Temperature; **SDS**: Safety Data Sheet; **TCSI**: Taiwan Chemical Substance Inventory; **TDG**: Transportation of Dangerous Goods; **TECI**: Thailand Existing Chemicals Inventory; **TSCA**: Toxic Substances Control Act (United States); **UN**: United Nations; **UNRTDG**: United Nations Recommendations on the Transport of Dangerous Goods; **vPvB**: Very Persistent and Very Bioaccumulative; **WHMIS**: Workplace Hazardous Materials Information System

**Sources of key data used to compile the Material Safety Data Sheet**


**Revision Date**

- 27.08.2021
The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8